Overview

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Status:
RECRUITING

Trial end date:
2027-10-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).

Phase:

PHASE2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

remibrutinib